3 Result: IBio
Market Buzz: CDI Trial Outcome Fuels Acurx Pharmaceuticals
October 02nd, 2023
Shares of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) surged by more than 20% in pre-market trading following the company's decision to discontinue its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, designed for the treatment . Read more
Triple Impact: iBio's Collaboration, Oracle's Strong Q4, and EVgo's Charging Network Growth Make Waves
June 12th, 2023
iBio, Inc. (NYSE American: IBIO) has partnered with the National Institute of Allergy and Infectious Diseases (NIAID) to explore the potential of the company's AI-driven epitope steering platform in developing a vaccine for Lassa fever, a severe and . Read more
Lucintel Forecasts Feed Enzyme Market to grow at a CAGR of 9% from 2019 to 2024
December 08th, 2021
Dallas, TX / CRWE PRESS RELEASE / Dec. 9, 2021 - According to the recent study the Feed Enzyme Market is projected to grow at a CAGR of 9% from 2019 to 2024. Growth in this market is primarily driven by increasing animal population, high cost of. Read more
Want To Find Some News?
News By Industries
Recent Post
-
February 27th, 2026February 26th, 2026
Treasury Sanctions Nicaraguan Officials Enabling the Murillo-Ortega Dictatorship's Repression
February 26th, 2026Kansas City Storm Names Cecil Stockdale as Head Coach for 2026 NJCP Season
February 26th, 2026Dallas Stampede Announces Open Tryouts for Scholarship Opportunities
February 25th, 2026
Member Login